Osseor (strontium ranelate)
- Region
- 🇪🇺 EU
- Active substance
- strontium ranelate
- Company
- Les Laboratoires Servier
- Status
- Withdrawn
- Therapeutic area
- Osteoporosis, Postmenopausal
- EU approval
- Mon 20 Sep 2004
- Application
- EMEA/H/C/000561
- ATC
- M05BX03
- Official record
- www.ema.europa.eu
Indication
Treatment of severe osteoporosis in postmenopausal women at high risk for fracture to reduce the risk of vertebral and hip fractures. Treatment of severe osteoporosis in adult men at increased risk of fracture. The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Protelos Withdrawn · Les Laboratoires Servier
- 🇪🇺 Ditelos Application withdrawn · Les Laboratoires Servier
- 🇪🇺 Issarlos Application withdrawn · Les Laboratoires Servier
Follow Osseor
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.